Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlconXSWX:ALC -1.65%70 3-Year EBITDA Growth Rate is 10.20% as of Mar. 2026, which is 1% above its 10-year median of 10.10. GuruFocus rates XSWX:ALC with a GF Score™ of 70/100 and a GF Value™ of CHF74.22 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Alcon ranks better than 52.31% on this metric.
During the past 12 months, Alcon's average EBITDA Per Share Growth Rate was -5.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 10.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alcon was 24.60% per year. The lowest was -6.00% per year. And the median was 10.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Alcon 3-Year EBITDA Growth Rate Related Terms
XSWX:ALC vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Alcon's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcon 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alcon's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Alcon's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 10.20% mean?
Alcon (XSWX:ALC) has a 3-Year EBITDA Growth Rate of 10.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alcon and its competitors. This is near median its historical median of 10.10. According to the industry distribution chart, Alcon ranks #330 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 47.7%.
Is Alcon's 3-Year EBITDA Growth Rate too high?
Alcon's current 3-Year EBITDA Growth Rate of 10.20% is near median its 10-year median of 10.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.65. Alcon's value of 10.20% is 33.3% above this industry median. Based on the distribution chart, Alcon ranks #330 out of 692 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Alcon has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #330 out of 692 companies for 3-Year EBITDA Growth Rate. This puts Alcon in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.65. Alcon's value of 10.20% is 33.3% above this benchmark. While the company's 10-year median is 10.10 vs. the industry median of 7.65, Alcon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.65, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alcon's current 3-Year EBITDA Growth Rate of 10.20% is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Alcon and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcon's current 3-Year EBITDA Growth Rate is 10.20%, which is near median its own 10-year median of 10.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALC) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF74.22, compared to a current price of CHF54.90 — trading 26% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 10.20%, which is near median its 10-year median of 10.10 and 33.3% above the Medical Devices & Instruments industry median of 7.65. Alcon's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Alcon (XSWX:ALC), the current 3-Year EBITDA Growth Rate is 10.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alcon (XSWX:ALC) Overvalued in 2026?
Based on GuruFocus' analysis, Alcon stock appears to be undervalued.
The current stock price of CHF54.90 is trading 26% below its estimated GF Value™ of CHF74.22.
GuruFocus considers Alcon to be Modestly Undervalued.
Key valuation signals for XSWX:ALC:
3-Year EBITDA Growth Rate: 10.20% (near median its 10-year median of 10.10)
GF Value™: CHF74.22 vs. price of CHF54.90 (26% below fair value)
Industry Position: 33.3% above the Medical Devices & Instruments median (#330 of 692)
No single metric tells the full story. See the XSWX:ALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
70GF Score
Get the complete analysis for XSWX:ALC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ALC has been successfully added to your 
